Psychedelics

Friday Feb 04, 2022 - 1:59 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, accomplished a host of major milestones in 2021, proving it is on the right path to success. The company was awarded a notice of allowance by the U.S. Patent and Trademark Office for its CYB004 (deuterated psychedelic tryptamine) for the treatment of anxiety disorders and FDA…

Thursday Feb 03, 2022 - 11:39 am

InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs to Present at Emerald Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, will give a presentation on “Artificial Intelligence for Craft Cannabis Products” at the Emerald Conference. Dr. Roggen’s presentation is scheduled to begin at 12:45 p.m. PT on Monday, Feb. 28, 2022. “Focusing…

Thursday Feb 03, 2022 - 10:25 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s board of directors. A pharmaceutical scientist, executive and global health social entrepreneur, Dr. Hale currently serves as chair of the board of the Multidisciplinary Association for Psychedelic Studies (“MAPS”). A non-profit research and…

Tuesday Feb 01, 2022 - 10:45 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Mydecine has announced that, in preparation for its FDA pre-Investigational New Drug (“IND”) meeting on Feb. 28, the company has submitted a pre-IND briefing package to the U.S. Food and Drug Administration (“FDA”) for a clinical study evaluating MYCO-001 in…

Monday Jan 31, 2022 - 3:33 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in an excellent position to tap into the opportunities offered by the smoking cessation market. In early 2021, one of the leading smoking cessation tools prescribed by physicians, Chantix, was pulled off the market for its cancer risk, leaving a large hole…

Monday Jan 24, 2022 - 12:08 pm

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Access of New Medicines, Treatment for Mental Health Conditions

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, recently announced its wholly owned ketamine infusion clinic chain, Ketamine Wellness Centers LLC (“KWC”), will open two new clinics in Salt Lake City, Utah, and Reno, Nevada, by February 2022. KWC, at that time, had cumulatively delivered over 60,000 treatments across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, and Washington. A recent article reads,…

Wednesday Jan 19, 2022 - 1:04 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Strengthening ‘Emerging Best-in-Class Position’ in Evolving Industry

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”). The notice was regarding Cybin’s patent application connected to its investigational deuterated psychedelic tryptamine compound, CYB004, for the potential treatment of anxiety disorders. “The receipt of this notice of allowance from the…

Wednesday Jan 19, 2022 - 9:18 am

InvestorNewsBreaks – Microdose Psychedelic Insights’ Upcoming Conference to Showcase Top Companies, Newest Opportunities Within Psychedelics Sector

Microdose Psychedelic Insights, the leading guide to the business of psychedelics, will be hosting the upcoming Psychedelic Capital: January 2022 Conference in an entirely virtual format on Jan. 27, 2022, starting at 1:30 p.m. EST. The event will shine the spotlight on some of the top companies, latest IPOs, newest opportunities and deepest industry insights within the psychedelics sector. As part of a bimonthly investor…

Tuesday Jan 18, 2022 - 1:11 pm

InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Releases Results of Harris Survey on Psychedelics as an Alternative Treatment

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that nearly two-thirds (65%) of Americans who suffer from anxiety, depression and PTSD believe that psychedelic medicine, including ketamine, psilocybin and MDMA, should be available to patients with treatment-resistant anxiety, depression or PTSD. The online survey included 953 adults living in the United States…

Tuesday Jan 18, 2022 - 12:13 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), The Newly Partner to Set the Gold Standard for Psychedelic-Assisted Therapies

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with The Newly Institute Inc. (“The Newly”), a Calgary, Alberta based company opening private inter-disciplinary mental health clinics across Canada. The companies will collaborate on expanding psychedelic-assisted psychotherapy to patients and,…

Thursday Jan 13, 2022 - 10:27 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has unveiled its Special Access Support and Supply Program (“SASSP”). The program provides products, services and support to hospitals, clinics and physicians in Canada who utilize psychedelic-assisted psychotherapy treatment. Health Canada recently added psilocybin and MDMA to its approved list of…

Tuesday Jan 11, 2022 - 11:57 am

InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Opens Salt Lake City Clinic

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its subsidiary, Ketamine Wellness Centers (“KWC”), has officially expanded operations into Utah with the opening of its Salt Lake City location. Acquired by Delic in September 2021, KWC currently operates 11 ketamine infusion treatment clinics across nine states, delivering more than 61,000 treatments…

Tuesday Jan 11, 2022 - 11:50 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures IRB Approval for Feasibility Study Using Kernel’s Quantitative Neuroimaging Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an Institutional Review Board (“IRB”) has approved a company-sponsored feasibility study. The study will use Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. As part of its sponsorship of the feasibility study, Cybin will retain an exclusive interest in any…

Monday Jan 10, 2022 - 10:52 am

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Present at HC Wainwright Bioconnect Virtual Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced details regarding its participation at today's HC Wainwright Bioconnect Virtual Conference. The company’s co-founder and CEO Matt Stang will present on Delic’s expansion strategy and industry outlook heading into 2022 and offer one-on-one meetings with investors. Interested parties should visit https://ibn.fm/eTcfl to register for…

Monday Jan 10, 2022 - 9:52 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, has announced its engagement of JBN Partners LLC to increase public awareness of and interest in the company, its management and its products. Under the collaboration, JBN will coordinate certain investor relations and corporate financial public relations with members of the…

Friday Jan 07, 2022 - 11:15 am

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Presence, Access Within Psychedelic Wellness Space

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, recently sought to expand its presence within psychedelic wellness, entering into a merger agreement with Ketamine Wellness Centers LLC (“KWC”). KWC boasts the nation’s largest chain of psychedelic wellness clinics. A recent article reads, “Under the terms of the deal, Delic agreed to acquire KWC’s chain of 10 ketamine infusion clinics, operating across Arizona,…

Thursday Jan 06, 2022 - 1:53 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in a recent episode of “Gamechangers LIVE.” The podcast series shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners.…

Wednesday Jan 05, 2022 - 10:15 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces January 2022 Health Care Conference Schedule

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase. The events are slated to be held virtually on Jan. 10-12, 2022. Tryp’s CEO and Chairman Greg McKee will provide an overview of the company and updates…

Tuesday Jan 04, 2022 - 2:02 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Support Low-Cost/No-Cost Psychedelic Clinic for Underserved Communities

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones to revolutionize mental health care. Among these, the company recently secured a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital. The hospital is part of Northwell Health, the largest health care system in New York State, and serves marginalized communities on the Upper…

Thursday Dec 30, 2021 - 11:52 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Expanding Robust Portfolio of Novel Compounds

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company, has aimed to transform the treatment of mental health disorders and addiction since its inception. The company has already developed first- and second-generation novel therapeutics designed to treat addiction, post-traumatic stress disorder (“PTSD”) and other mental health conditions. “Mydecine recently released its third-quarter 2021 update and a noteworthy announcement for the 2021 calendar year.…

Tuesday Dec 28, 2021 - 1:42 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Witnessing Swift Advancement in R&D Pipeline, Overall Business

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating report for Q2 2021, with notable company milestones and achievements highlighted. The company plans to move through the ongoing remaining preclinical studies for its CYB003 novel deuterated psilocybin analog and submit an investigational new drug application and clinical trial application…

Monday Dec 27, 2021 - 12:48 pm

InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Flagship Event Provides Pioneering Insights into Business, Psychedelics, Overall Wellness

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, held the Meet Delic Conference in November in Las Vegas, Nevada. The event, which featured over 60 thought leaders, medical professionals and wellness advocates, drew more than 2,500 attendees, becoming the largest psychedelic wellness and business conference in the world. “The Meet Delic conference aimed to raise awareness of the science-backed benefits of psychedelics…

Tuesday Dec 21, 2021 - 10:52 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming January Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in two premier events: the 11th annual LifeSci Partners Annual Corporate Access Event and the H.C. Wainwright Bioconnect Conference. Cybin CEO Doug Drysdale will participate in both upcoming virtual investor events. At the LifeSci Partners event, scheduled for Jan. 5–7, 2021, Drysdale will be involved in a panel…

Monday Dec 20, 2021 - 2:20 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) recently released financials and a business update for the third quarter ending Sept. 30, 2021. During this reporting period, the company filed three patent applications; successfully synthesized a novel psilocin analogue with improved pharmaceutical properties; launched Mindleap 2.0, an updated version of its proprietary virtual health platform; and completed its spin-out transaction of ALT House Cannabis Inc. “The…

Wednesday Dec 15, 2021 - 11:28 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notice of Allowance from U.S. Patent Office for Exclusive Anxiety Disorder Treatment

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”). The award is for CYBN’s patent application related to CYB004, an investigational deuterated psychedelic tryptamine compound developed for the potential treatment of anxiety disorders. According to the announcement, allowed claims under the award also include other forms…

Monday Dec 13, 2021 - 12:38 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Developing Safer, More Effective Psilocybin Therapies for Patients

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs. A recent article quotes CEO Doug Drysdale as saying, “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental health care, but few companies have addressed…

Friday Dec 10, 2021 - 12:06 pm

InvestorNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’

Mind Medicine (“MindMed”) (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, recently met with the United States Food and Drug Administration (“FDA”) Center for Devices and Radiological Health (“CDRH”) with consultation from the Center for Drug Evaluation and Research (“CDER”). The device pre-submission meeting that took place on Oct. 25, 2021, was concerning several key points for ongoing development of…

Thursday Dec 09, 2021 - 8:30 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Establishment of Regulatory Advisory Board, Strategic Appointments

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory advisory board (“RAB”) and has appointed Joga Gobburu, B.Pharm (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members. Dr. Gobburu is a world-recognized scientific leader in pharmacometrics and a professor at…

Wednesday Dec 08, 2021 - 2:37 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Clinical Trials, Focus Puts It ‘In Pretty Rarefied Air’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is advancing toward the launch of four phase 2a studies of its two novel drug candidates, TRP-8802 and TRP-8803, for treating fibromyalgia, phantom limb pain, complex regional pain syndrome (“CRPS”) and select eating disorders. Tryp filed an IND with the U.S. Food and Drug Administration in September for treating overeating disorders in Florida and filed its second IND application…

Wednesday Dec 08, 2021 - 10:50 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Moving Rapidly to Progress CYB003 Toward Clinical Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced a confirmed scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) for the first quarter of calendar year 2022. According to the update, this program milestone brings Cybin closer to advancing its lead investigational candidate CYB003 into clinical development for the treatment of major…

Monday Dec 06, 2021 - 10:46 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. According to the update, the application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of…

Friday Dec 03, 2021 - 10:08 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the Second Annual H.C. Wainwright Psychedelics Conference. The event is slated to be held virtually on Dec. 6, 2021. Tryp’s chairman and CEO Greg McKee will provide an overview of the business and its pipeline, including the upcoming…

Friday Dec 03, 2021 - 9:30 am

InvestorNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Lucid-MS Featured in InvestmentPitch Video, CEO to Present at H.C. Wainwright Psychedelics Virtual Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data demonstrating the potentially disease-modifying effects of Lucid-MS, its lead drug candidate for the potential treatment of multiple sclerosis in the animal models of MS. According to the update, InvestmentPitch.com has produced a video discussing the news. Based on…

Thursday Dec 02, 2021 - 9:49 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Tryp's Investigational New Drug (“IND”) application is complete and that the company may proceed with its clinical study in fibromyalgia. The trial, which the company expects to…

Thursday Dec 02, 2021 - 8:30 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the company’s lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS. “Lucid-MS has demonstrated the potential to prevent…

Wednesday Dec 01, 2021 - 2:40 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently submitted an Investigational New Drug (“IND”) application to the U.S. FDA to evaluate its TRP-8802 clinical candidate in a phase 2a clinical trial to explore psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia. The study, which is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D., will involve 20 fibromyalgia…

Tuesday Nov 16, 2021 - 9:30 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Strategic Appointment of World-Renowned Immunologist and Cytokine Expert

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has announced the appointment of Eleanor N. Fish, Ph.D., to its research and clinical advisory board. Dr. Fish is an accomplished researcher in the areas of immunology and inflammatory disorders and a member of the government of Canada’s expert scientific panel to…

Monday Nov 15, 2021 - 12:19 pm

InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Committed to Making Psychedelic Wellness Accessible to the Masses

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is well positioned to capitalize on the psychedelic industry’s continued growth trajectory. “The company owns and operates a self-sustaining ecosystem of businesses in the psychedelic space consisting of media, science and health business verticals. Delic has been particularly active on the mergers and acquisitions front over the last several months in a bid to…

Thursday Nov 11, 2021 - 12:46 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Partnerships to Facilitate TRP-8803’s Advancement

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently announced a collaboration with researchers at the University of Wisconsin-Madison as part of preparations toward planned phase 2b studies. Under the partnership, Dr. Paul Hutson, PharmD, and Dr. Christopher Nicholas, Ph.D., will support clinical pharmacology studies for TRP-8803, Tryp’s proprietary drug formulation with a novel route of administration. Once completed, the studies will provide additional regulatory support for…

Tuesday Nov 09, 2021 - 10:10 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release Q2 2021 Financial Results, Host Call

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is planning to release its Q2 2021 financial report on Nov. 15, 2021. The report will cover the period ended Sept. 30, 2021. The company is also planning on hosting a conference call and webcast the same day, which is scheduled to begin at 4:30 p.m. EST. The call will be…

InvestorNewsBreaks

NewsBreak Category: Psychedelics

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions